gression analysis showed that body mass index, age, number of bowel resections, topic steroids, and azathioprine correlated with the Z scores. Cumulative steroid dose, topic steroids, age and bowel resection were found to be predictors for a pathological T score. At the femoral neck, regression analysis showed that body mass index, age, topic steroids, and azathioprine correlated with the Z scores. Only a low body mass index was a signifi cant predictor for pathological femoral T scores. Conclusions: Osteopenia and osteoporosis are commonly found in IBD patients. Steroid treatment and bowel resection were signifi cant risk factors for osteoporosis of the lumbar spine. However, disease-inherent factors also appear to confer a major risk, indicating that the BMD should be determined in all IBD patients, irrespective of steroid treatment.
and vitamin D defi ciency, small bowel resection, hypogonadism, corticosteroid treatment [2] , smoking [3] and genetic factors [4] . Crohn's disease (CD) itself also seems to be an important risk factor for low BMD [5] . A low BMD may already be present at the time of initial diagnosis of CD [6] . CD patients without previous treatment appear to have a signifi cantly lower average BMD of the lumbar vertebrae when compared with ulcerative colitis (UC) patients [7] . Furthermore, the BMD in CD patients increases after induction of remission by azathioprine [8] . These fi ndings suggest that CD itself plays an important role in the development of osteopenia/osteoporosis, and that a low BMD cannot be attributed solely to treatment with steroids. Corticosteroids have been shown to reduce the BMD [2, [9] [10] [11] [12] [13] [14] [15] [16] , although the data are confl icting [5, 6, [17] [18] [19] [20] [21] .
IBD patients have up to 40% more fractures than the general population [22] , with an increased risk of both vertebral and hip fractures [23] . Analysis of the risk factors for the development of osteoporosis could help to identify those IBD patients who have a higher risk of fractures. We therefore aimed at analyzing the risk factors for a low BMD in our cohort of unselected IBD patients, so as to optimize BMD monitoring and treatment in at-risk patients.
Patients and Methods

Study Design and Patients
The study was a cross-sectional analysis of a local IBD cohort. At the time of analysis, 137 patients were registered in the IBD cohort of the University Hospital of Zürich. All patients were diagnosed by a combination of radiology, endoscopy, and histology. BMD was determined by dual-energy X-ray absorptiometry (DEXA) in 88 (64%) patients (55 CD, 30 UC, 3 indeterminate colitis). Only patients with isolated proctitis and no prior steroid treatment were initially excluded from the DEXA analysis. Demographic and clinical data of these patients were obtained by review of the medical records and by a questionnaire sent to all patients. In 14 patients, a diagnosis of arthritis was documented in the fi les; of these, 6 patients were classifi ed as having seronegative spondyloarthropathy. There was 1 case of chronic hepatitis C and 1 case of primary sclerosing cholangitis, and 6 patients were diagnosed as having liver steatosis upon abdominal ultrasound. One case of Hashimoto thyroiditis and 1 patient with subclinical hyperthyroidism were also included.
BMD Measurement
The BMD of the lumbar L2-L4 vertebrae and of the femoral neck was determined by standard DEXA at the Department of Rheumatology, University Hospital of Zürich. The results are expressed as either Z scores or T scores. Z scores indicate the number of SD from the normal sex-and age-specifi c mean value. T scores were calculated in relation to sex-matched healthy young adults at the age of peak bone mass as the reference group. According to the World Health Organization criteria, osteoporosis was defi ned as a T score below -2.5 SD, and osteopenia was defi ned by a T score below -1 SD, but not more than 2.5 SD below the average. Data from the reference groups were supplied by the equipment manufacturer.
Statistics
The two-tailed Mann-Whitney U test was used to study the relationship between Z scores and the following potential individual risk factors: diagnosis, sex, involvement of small bowel, weight loss, anemia, bowel resection, topic steroid treatment, azathioprine and methotrexate treatments, alcohol and nicotine consumption, and family history. Other risk factors were not studied because the subgroups were too small for a meaningful analysis. To determine the factors predictive of Z scores, stepwise regression with backward selection was performed with the following independent variables: diagnosis (CD vs. UC), sex, age, BMI, involvement of small bowels, bowel resection, family history of IBD, steroids (daily steroid dose, cumulative steroid dose, and topic steroid treatment), azathioprine and methotrexate treatments, as well as alcohol and nicotine consumption. The two-tailed Mann-Whitney U test was also used to study the relationship between T scores and individual risk factors. To determine factors predictive of T scores, the patients were divided into two groups (normal BMD with T scores above -1 SD versus pathological BMD with T scores below -1 SD), and stepwise logistic regression with backward selection was performed. p ! 0.05 was considered statistically signifi cant.
Results
Characteristics of Patients Assessed by DEXA
The BMD was measured by DEXA in 88 IBD patients. DEXA was performed in 55 CD patients (30 male, 25 female, mean age 39.0 years) and in 30 UC patients (19 male, 11 female, mean age 44.2 years) with a disease duration of 8.5 8 7.2 and 8.7 8 7.4 years, respectively ( table 1 ). The BMD was additionally measured in 3 patients with indeterminate colitis. The small bowel was affected in 62% of the CD patients, whereas 10% of the UC patients had involvement of the terminal ileum. Small bowel resections had been performed in one third of the CD patients. Nearly all IBD patients had been treated with steroids at some stage of their disease (90% of the CD and 97% of the UC patients), with a higher cumulative systemic steroid dose in UC than in CD patients (32.6 and 20.6 g, respectively).
Prevalence of Osteopenia and Osteoporosis in the IBD Patients
Pathological BMD (osteopenia or osteoporosis) was more frequently observed at the lumbar spine than at the femoral neck (in 57 and 47% of the IBD patients, respectively; fi g. 1 ). Osteoporosis, defi ned as a T score below -2.5 SD, was found in 14% of the IBD patients (in 18% of the CD patients and in 10% of the UC patients) at the lumbar spine and in 5% of the IBD patients (in 4% of the CD patients and in 7% of the UC patients) at the femoral neck. Osteopenia, defi ned as a T score between -1 and -2.5 SD, was present in 40% of the IBD patients.
Assessment of the Risk Factors for Low Z Scores
The distribution of the Z scores at lumbar spine and femoral neck among CD und UC patients is shown by box plots in fi gure 2 . The median values for CD patients were -1.15 at the lumbar spine and -0.6 at the femoral neck. The median values for UC patients were -0.8 at the lumbar spine and -0.2 at the femoral neck. To analyze the contribution of individual potential risk factors to low BMD values, we performed Mann-Whitney U tests. Patients who had undergone bowel resection showed a signifi cantly lower lumbar Z score than patients without bowel resections (p ! 0.05). Other statistically signifi cant individual risk factors were found neither at the lumbar spine nor at the femoral neck. We next performed stepwise regression analysis to identify predictive factors for low Z scores. Patients who had undergone bowel resections or had been treated with topic steroids and azathioprine had a signifi cantly increased risk of low lumbar Z scores. Additionally, patients with a low BMI and young- er patients had a signifi cantly increased risk of having low lumbar Z scores. The same predictive factors were found for femoral Z scores, except for bowel resection which did not reach statistical signifi cance (p = 0.18; table 2 ).
Assessment of the Risk Factors for Low T Scores
For analysis of the risk factors for low T scores, the patients were divided into two groups according to the WHO guidelines: (1) patients with normal T scores (above -1 SD) and (2) patients with osteopenia or osteoporosis (T score below -1 SD). The patients with a pathological lumbar T score were signifi cantly younger, had a lower BMI, and had received more corticosteroid treatments (longer duration of steroid therapy and higher cumulative steroid doses). The steroid dose is expressed as grams of prednisone or prednisone-equivalent dose. These results are shown in table 3 and in fi gure 3 . Table 3 shows the median values of these risk factors in patients with normal and pathological BMD values. The box plots shown in fi gure 3 show the distribution of the cumulative steroid Exp(B) indicates the increase in the risk of a T score < -1 conferred by the respective parameter (this can be interpreted as an odds ratio). In the case of the cumulative steroid dose, the Exp(B) value indicates a 1.022 greater risk of a T score < -1 with a cumulative steroid dose of 1 g of prednisone or prednisone-equivalent dose; for 10 g cumulative steroids, this risk increases to 1 ( table 3 ) . In stepwise regression analysis, pathological femoral T scores were signifi cantly correlated with low BMI, topic steroids and azathioprine treatment ( table 4 ) .
Discussion
The main fi ndings of this study can be summarized as follows: (1) osteopenia and osteoporosis show a high prevalence in IBD patients, with more than 50% being affected, and (2) major risk factors for the development of osteopenia/osteoporosis are corticosteroid treatment and bowel resections; however, after exclusion of all other variables, disease activity per se appears to confer a relevant independent risk.
We found a 14% prevalence of osteoporosis at the lumbar spine in our cohort of Swiss IBD patients. This is comparable with another Swiss study [24] that recently reported a 9.7% prevalence of osteoporosis in IBD patients seen in specialist gastroenterology practice. Earlier studies reported an even higher prevalence of osteoporosis in IBD patients of around 30% [1, 18, 25] . The reason for this is not clear, since more patients were excluded in these studies compared to our investigation -one study [25] excluded patients with bowel resections or a lifetime steroid dose 1 25 g, whereas another study [1] excluded patients receiving treatment for osteoporosis or patients with severe malabsorption. It is of note, however, that the proportion of IBD patients with osteopenia was 40% in our study; this underlines the importance of carefully assessing all IBD patients for BMD and initiating appropriate treatment in those with a pathological BMD. Relevance and effi ciency of bisphosphonates in the treatment of these patients are subject of continued debate [26] [27] [28] [29] [30] . Until further studies have clearly shown the clinical benefi t of bisphosphonates in osteoporosis associated with IBD, calcium and vitamin D should remain the baseline treatment in osteopenic and osteoporotic patients.
In our IBD cohort, in both CD and UC patients, the lumbar spine was found to be affected more often by a pathological BMD than the femoral neck. This fi nding is surprising, because most studies have found a higher prevalence of osteoporosis at the femoral neck [5, 18, 25, [31] [32] [33] . There is no obvious reason for this discrepancy. It has been reported that treatment with corticosteroids results in bone loss, especially at trabecular bone sites [34] such as the lumbar spine. There was, however, no evidence for excessive steroid treatment in our cohort as compared with the other studies.
Multivariate regression analysis identifi ed several predictive variables of reduced BMD at the lumbar spine. One predictive factor was the BMI. This relationship has been described in several previous studies [17, 18, [35] [36] [37] , and follow-up studies with repeated BMD measurements have shown that a reduction in BMI leads to bone loss [20, 38] . Furthermore, young age was identifi ed as a predictive variable for both low Z and T scores, although the regression coeffi cients were low (0.020 and 0.025 for femoral and lumbar Z scores, respectively). This suggests that, at least in our cohort, younger IBD patients had a mildly elevated risk of osteoporosis than older patients. This could be due to a more active disease in young patients, leading to osteoporosis via circulating cytokines [39] which affect osteoclast [40] and osteoblast function [41] . This observation is in agreement with results of a study showing that IBD patients younger than 18 years at the time of diagnosis are at risk of osteoporosis [32] .
The hypothesis that the disease activity is an independent risk factor for the development of osteoporosis is supported by the fi nding that topic steroids and azathioprine were signifi cant predictors of BMD. So far, no detrimental effect of azathioprine on BMD has been shown. We assume that azathioprine is negatively correlated with BMD, because it is used in IBD patients with high infl ammatory activity requiring additional immunosuppressive medication. Contrary to azathioprine, methotrexate treatment was not found to be correlated with BMD which may be due to the low number of patients treated: whereas 61 patients (69%) were treated with azathioprine, only 8 patients (9%) had received methotrexate. The negative effect of topic steroid treatment on BMD could in part be attributable to a systemic effect of local steroids.
The deleterious effect of systemic steroids on BMD is supported by the fi nding that patients with a pathological BMD had received a more intense steroid treatment (higher cumulative steroid dose and longer duration of steroid therapy). This confi rms previous observations showing that systemic corticosteroids are a risk factor for osteoporosis in CD patients [2] . In particular, high lifetime systemic steroid doses 1 10 g have been reported to be correlated with a low BMD [12, 14] .
Multivariate analysis further revealed a history of bowel resections as a signifi cant predictive variable of low BMD values. This issue is controversial in the literature, since some studies have described bowel resections as a risk factor [14, 18] , whereas others have not found a correlation [12, 42] . In our cohort, patients with a history of bowel resection had a threefold risk of a pathological BMD at the lumbar spine. One possible explanation for this relationship is that bowel resections lead to a malabsorptive state, e.g., for vitamin D [43] or vitamin K [44] . The role of the nutritional status in the development of osteopenia/osteoporosis is supported by the fi nding that a low BMI is a risk factor for reduced BMD, as described above. An alternative explanation, however, is that bowel resections are a sign of severe disease, leading to systemic infl ammation and complications which necessitate a surgical intervention.
One limitation of our study is that we did not apply strict exclusion criteria, in order to include a broad spectrum of IBD patients in our analyses. Only patients with isolated proctitis and no prior steroid treatment were initially excluded from the DEXA analysis. Data from BMD measurements were available for 88 patients (64%) in our cohort. When patients assessed by DEXA are compared with the total IBD cohort, the mean disease duration was longer (8.3 vs. 7.6 years), more patients had received steroid therapy (93 vs. 82%), and more patients had a history of bowel resection (28 vs. 24%). A selection bias, which could affect prevalence reportings in this study, cannot be excluded with certainty. Moreover, this study cannot prove that corticosteroids or bowel resections are causes of osteoporosis in IBD patients. The regression analyses performed are only able to provide correlative evidence for the involvement of different risk factors in the development of osteoporosis in IBD patients.
In summary, our results show that the prevalence of osteopenia and osteoporosis is high in a Swiss cohort of IBD patients. Major risk factors for low BMD values were corticosteroid treatment and a history of bowel resection, although a relevant risk is conferred by disease activity per se, irrespective of other variables analyzed. Moreover, the high prevalence of osteopenia reported in this study underlines the importance of monitoring by DEXA not only high-risk patients, but all IBD patients, and of initiating appropriate treatment in patients with low BMD values. Whether antiresorptive therapy with bisphosphonates in addition to calcium and vitamin D helps to prevent fractures in IBD patients with a low BMD remains to be evaluated.
